Please assess the completion status of the following clinical trial:

Trial Title: ECI301 and Radiation for Advanced or Metastatic Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
* INCLUSION CRITERIA:~2.1.1.1 Age greater than or equal to18 years.~2.1.1.2 Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.~2.1.1.3 Life expectancy of greater than 3 months~2.1.1.4 Histologically confirmed cancer~2.1.1.5 Extracranial metastatic cancer or locally advanced cancer for which palliative radiotherapeutic management would be appropriate (no more than two sites will be treated on this trial)~2.1.1.6 Patients must have measurable or evaluable disease at the site(s) requiring radiation~2.1.1.7 Adequate marrow and organ function defined as~* absolute neutrophil count (ANC) \> 1.5 times 10(9)/L,~* platelet count \> 100 times 10(9),~* hemoglobin \>9 g/L.~* creatinine clearance greater than or equal to 60 mL/min/1.73 m(2) for patients with creatinine levels above institutional normal~* serum bilirubin \<1.5 times upper limit reference range (ULRR),~* alanine aminotransferase (ALT), aspartate aminotransferase (AST), or~alkaline phosphatase (ALP) \<2.5 times the ULRR (\<5 times the ULRR in the presence~of liver metastases)~2.1.1.8 Female patients of childbearing potential must either be surgically sterile to prevent pregnancy, be at least 1-year post-menopausal, or have had no menses for 12 months, or agree to use reliable methods of contraception (oral contraceptives, barrier methods, approved contraceptive implant, long-term injectable contraception, copper banded intrauterine device, tubal ligation or abstinence) from time of screening until 4 weeks after discontinuing study treatment. It is not known whether ECI301 has the capacity to induce hepatic enzymes so hormonal contraceptives should be combined with a barrier method of contraception.~2.1.1.9 Male patients must agree to use barrier contraception (i.e. condoms) and refrain from donating sperm from the start of dosing until 16 weeks after discontinuing study treatment. If male patients wish to father children, they should be advised to arrange for freezing of sperm prior to the start of study treatment.~EXCLUSION CRITERIA:~2.1.2.1 Pregnant or lactating females~2.1.2.2 Contraindications to radiotherapy (i.e. prior radiotherapy to the intended treatment site)~2.1.2.3 Untreated or previously treated but progressive intracranial metastases (Patients with previously treated intracranial metastases should have no clinical evidence of progression and be at least 4 weeks from therapy for intracranial metastases)~2.1.2.4 Need for emergent radiotherapy (defined as need for radiotherapy within 24 hours of consultation at the judgment of the treating radiation oncologist)~2.1.2.5 Active treatment with immunosuppressive therapy and subjects taking systemic corticosteroid therapy for any reason including replacement therapy for hypoadrenalism~2.1.2.6 Chemotherapy, radiation therapy, Tamoxifen or investigational therapy during the 4 weeks prior to initiation of protocol therapy~2.1.2.7 History of rheumatoid arthritis, systemic lupus erythematosus, Sjogren's disease, sarcoidosis, vasculitis, polymyositis, temporal arteritis or any other autoimmune disease~2.1.2.8 History of organ transplant~2.1.2.9 Human immunodeficiency virus (HIV), Hepatitis B, or Hepatitis C positivity~2.1.2.10 Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements~2.1.2.11 Use of excluded immune modulating medications within 4 weeks prior to protocol therapy, or requirement for concurrent use.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer (Type: EXPERIMENTAL): ECI301 Dose level 1 - 25 ug/kg and Radiation for Advanced or Metastatic Cancer

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility